Boerhaavia diffusa Extract Acts as a Specific Antituberculosis Agent in Vitro Against Mycobacterium tuberculosis H37Rv Infection.

ABSTRACT

The present study investigated Boerhaavia diffusa extract against Mycobacterium tuberculosis H37Rv (M.tb) infection in vitro and explored the underlying mechanism. The study demonstrated that Boerhaavia diffusa extract significantly (p < 0.05) reduced RAW 264.7 and A549 cell viability in concentration dependent manner. In BEAS-2B, NuLi-1 cells and splenocytes no significant (p > 0.05) reduction in viability was observed on treatment with 2.5 to 20 mg/L concentrations of Boerhaavia diffusa. The M. tb­induced increase in TNF­α expression was significantly (p < 0.05) reversed by Boerhaavia diffusa treatment in RAW 264.7 and BEAS-2B cells. Moreover, Boerhaavia diffusa treatment significantly (p < 0.05) inhibited M.tb­induced increase in IL-6 and IL­1ß expression in RAW 264.7 and BEAS-2B cells. Boerhaavia diffusa treatment of RAW 264.7 and BEAS-2B cells significantly (p < 0.05) reversed M.tb­induced increase in iNOS and COX­2 expression. Additionally, in Boerhaavia diffusa treated cells M.tb­induced increase in NO release was significantly (p < 0.05) reduced compared to untreated cells. In summary, Boerhaavia diffusa treatment inhibits pro-inflammatory cytokine production, NO release and regulate immunomodulatory mediators in M.tb­infected RAW 264.7 and BEAS-2B cells. Therefore, Boerhaavia diffusa may be developed as a therapeutic agent for treatment of M.tb­infection.